133 related articles for article (PubMed ID: 33216547)
21. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
22. Quinoline and thiazolopyridine allosteric inhibitors of MALT1.
Scott DA; Hatcher JM; Liu H; Fu M; Du G; Fontán L; Us I; Casalena G; Qiao Q; Wu H; Melnick A; Gray NS
Bioorg Med Chem Lett; 2019 Jul; 29(14):1694-1698. PubMed ID: 31129051
[TBL] [Abstract][Full Text] [Related]
23. Antiapoptotic properties of MALT1 protease are associated with redox homeostasis in ABC-DLBCL cells.
Zhu L; Tang F; Lei Z; Guo C; Song Y; Huang J; Xia X
Mol Carcinog; 2019 Dec; 58(12):2340-2352. PubMed ID: 31556968
[TBL] [Abstract][Full Text] [Related]
24. Attacking MALT1 for ABC-DLBCL therapy.
Krappmann D
Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
[No Abstract] [Full Text] [Related]
25. Discovery of 3-(4-(2-((1
Zhang C; Qi W; Li Y; Tang M; Yang T; Liu K; Chen Y; Deng D; Xiang M; Chen L
J Med Chem; 2021 Feb; 64(4):1966-1988. PubMed ID: 33593051
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.
Chen Y; Yuan X; Zhang W; Tang M; Zheng L; Wang F; Yan W; Yang S; Wei Y; He J; Chen L
J Med Chem; 2019 Feb; 62(3):1577-1592. PubMed ID: 30629434
[TBL] [Abstract][Full Text] [Related]
27. Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.
Heng H; Wang Z; Li H; Huang Y; Lan Q; Guo X; Zhang L; Zhi Y; Cai J; Qin T; Xiang L; Wang S; Chen Y; Lu T; Lu S
Eur J Med Chem; 2019 Aug; 176():248-267. PubMed ID: 31103903
[TBL] [Abstract][Full Text] [Related]
28. Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
Lim SM; Jeong Y; Lee S; Im H; Tae HS; Kim BG; Park HD; Park J; Hong S
J Med Chem; 2015 Nov; 58(21):8491-502. PubMed ID: 26496175
[TBL] [Abstract][Full Text] [Related]
29. A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1/regulatory T-cell homeostasis.
Dumont C; Sivars U; Andreasson T; Odqvist L; Mattsson J; DeMicco A; Pardali K; Johansson G; Yrlid L; Cox RJ; Seeliger F; Larsson M; Gehrmann U; Davis AM; Vaarala O
PLoS One; 2020; 15(9):e0222548. PubMed ID: 32870913
[TBL] [Abstract][Full Text] [Related]
30. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
31. Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2.
Heightman TD; Berdini V; Bevan L; Buck IM; Carr MG; Courtin A; Coyle JE; Day JEH; East C; Fazal L; Griffiths-Jones CM; Howard S; Kucia-Tran J; Martins V; Muench S; Munck JM; Norton D; O'Reilly M; Palmer N; Pathuri P; Peakman TM; Reader M; Rees DC; Rich SJ; Shah A; Wallis NG; Walton H; Wilsher NE; Woolford AJ; Cooke M; Cousin D; Onions S; Shannon J; Watts J; Murray CW
J Med Chem; 2021 Aug; 64(16):12286-12303. PubMed ID: 34387469
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors.
Wu G; Wang H; Zhou W; Zeng B; Mo W; Zhu K; Liu R; Zhou J; Chen C; Chen H
Bioorg Med Chem; 2018 Jul; 26(12):3321-3344. PubMed ID: 29751989
[TBL] [Abstract][Full Text] [Related]
33. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
[TBL] [Abstract][Full Text] [Related]
35. Targeting lymphomas through MALT1 inhibition.
Fontan L; Melnick A
Oncotarget; 2012 Dec; 3(12):1493-4. PubMed ID: 23455603
[No Abstract] [Full Text] [Related]
36. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
37. Discovery of a Potent and Selective PI3Kδ Inhibitor (
Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
[TBL] [Abstract][Full Text] [Related]
38. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Gingrich DE; Lisko JG; Curry MA; Cheng M; Quail M; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Haltiwanger RC; Wells-Knecht K; Ott GR; Ghose AK; Ator MA; Ruggeri B; Dorsey BD
J Med Chem; 2012 May; 55(10):4580-93. PubMed ID: 22564207
[TBL] [Abstract][Full Text] [Related]
39. MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.
Gehring T; Erdmann T; Rahm M; Graß C; Flatley A; O'Neill TJ; Woods S; Meininger I; Karayel O; Kutzner K; Grau M; Shinohara H; Lammens K; Feederle R; Hauck SM; Lenz G; Krappmann D
Cell Rep; 2019 Oct; 29(4):873-888.e10. PubMed ID: 31644910
[TBL] [Abstract][Full Text] [Related]
40. Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma.
Wang X; Blackaby W; Allen V; Chan GKY; Chang JH; Chiang PC; Diène C; Drummond J; Do S; Fan E; Harstad EB; Hodges A; Hu H; Jia W; Kofie W; Kolesnikov A; Lyssikatos JP; Ly J; Matteucci M; Moffat JG; Munugalavadla V; Murray J; Nash D; Noland CL; Del Rosario G; Ross L; Rouse C; Sharpe A; Slaga D; Sun M; Tsui V; Wallweber H; Yu SF; Ebens AJ
J Med Chem; 2019 Feb; 62(4):2140-2153. PubMed ID: 30715878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
